Core Viewpoint - In recent trading, Yingke Medical experienced a decline of 2.17% with a transaction volume of 517 million yuan, indicating a negative sentiment in the market [1] Financing and Margin Trading - On January 16, Yingke Medical had a financing buy amount of 47.01 million yuan and a financing repayment of 65.46 million yuan, resulting in a net financing outflow of 18.45 million yuan [1] - The total margin trading balance for Yingke Medical as of January 16 is 571 million yuan, with a financing balance of 559 million yuan, representing 2.10% of the circulating market value, which is below the 20th percentile level over the past year [1] - In terms of securities lending, 3,500 shares were repaid and 8,400 shares were sold on January 16, with a selling amount of 348,500 yuan, while the securities lending balance is 11.55 million yuan, exceeding the 80th percentile level over the past year [1] Financial Performance - For the period from January to September 2025, Yingke Medical achieved an operating income of 7.425 billion yuan, reflecting a year-on-year growth of 4.60%, and a net profit attributable to shareholders of 924 million yuan, which is a 34.47% increase year-on-year [2] Shareholder Information - As of September 30, 2025, Yingke Medical had 47,300 shareholders, a decrease of 21.11% from the previous period, while the average number of circulating shares per person increased by 25.65% to 9,832 shares [2] - The top ten circulating shareholders include notable entities such as Huabao Zhongzheng Medical ETF and E Fund Growth Enterprise ETF, with some shareholders reducing their holdings while others increased or newly entered [4] Dividend Distribution - Yingke Medical has distributed a total of 1.903 billion yuan in dividends since its A-share listing, with 245 million yuan distributed over the past three years [3]

Group 1 - The core point of the article is that Yingke Medical (300677) experienced a stock price decline of 2.17% on January 16, 2026, closing at 41.49 yuan with a trading volume of 123,400 shares and a transaction amount of 517 million yuan [1] Group 2 - On January 16, 2026, the main funds saw a net outflow of 20.20 million yuan, while speculative funds had a net inflow of 41.11 million yuan, and retail investors experienced a net outflow of 20.91 million yuan [2][4] - Yingke Medical held its first extraordinary general meeting of shareholders in 2026 on January 16, where a legal opinion was provided by Gao Peng (Shanghai) Law Firm regarding the meeting's procedures and results [2][3] - The meeting had 495 attendees representing 51,155,851 shares, accounting for 7.8477% of the total voting shares, and approved the proposal to purchase directors and senior management liability insurance with 99.1466% in favor [3][4]

Core Viewpoint - The company, Yingke Medical, announced the approval of a proposal to purchase liability insurance for directors and senior management during its first extraordinary general meeting of shareholders in 2026 [2] Group 1 - The extraordinary general meeting was held on January 16 [2] - The proposal regarding the purchase of liability insurance was specifically for directors and senior management [2]

Core Viewpoint - On January 16, 2026, Yingke Medical (300677) reported a closing price of 41.49 yuan, reflecting a decline of 2.17% from the previous trading day, with a total market capitalization of 27.183 billion yuan [1] Group 1: Stock Performance - The stock opened at 41.98 yuan, reached a high of 42.66 yuan, and a low of 41.4 yuan on the same day [1] - The trading volume amounted to 517 million yuan, with a turnover rate of 2.65% [1] Group 2: Shareholder Meeting - The company held its first extraordinary general meeting of 2026 on January 16, where a proposal to purchase liability insurance for directors and senior management was approved [1] - The meeting was convened by the board of directors and conducted through both in-person and online voting, with 495 shareholders and proxies present, representing 51,155,851 shares, or 7.8477% of the total voting shares [1] - The proposal received overwhelming support, with 99.1466% of the votes in favor, while the opposition and abstention rates were 0.7226% and 0.1308%, respectively [1] - Gaopeng (Shanghai) Law Firm provided a legal opinion confirming the legality and validity of the meeting's procedures and results [1]

法律意见书 高朋（上海）律师事务所 关于英科医疗科技股份有限公司 2026 年第一次临时股东会的 上海 南京 杭州 天津 深圳 扬州 泰州 2026 年 1 月 中国上海市徐汇区虹桥路 500 号中城国际大厦 23 楼 邮编：200030 电话/Tel：（8621）5039-2800 传真/Fax：（8621）5039-2800 网址：http://www.gaopenglaw.com 北京 www.gaopenglaw.com 中国·上海·徐汇区虹桥路 500 号 中城国际大厦 23 楼 23/F CURA International Center , No 500 HongQiao Road , XuHui District , Shanghai , 200030 ,China 电话/Tel：（8621）5039-2800 传真/Fax：（8621）5039-2800 www.gaopenglaw.com 高朋（上海）律师事务所 关于英科医疗科技股份有限公司 2026 年第一次临时股东会的 法律意见书 致：英科医疗科技股份有限公司 高朋（上海）律师事务所（以下简称"本所"）接受英科医疗科技股份有限 公司（ ...

证券代码：300677 证券简称：英科医疗 公告编号：2026-002 英科医疗科技股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会没有出现否决提案的情形。 2、本次股东会不涉及变更以往股东会已通过的决议的情形。 一、会议召开情况和出席情况 1、会议召开时间： 中小股东出席的总体情况：通过现场和网络投票的中小股东及股 东代理人495人，代表股份51,155,851股，占公司有表决权股份总数（扣 除公司回购专用账户股份数量）的7.8477％。其中：通过现场投票的 股东及股东代理人2人，代表股份22,200股，占公司有表决权股份总 数（扣除公司回购专用账户股份数量）的0.0034％。通过网络投票的 股东493人，代表股份51,133,651股，占公司有表决权股份总数（扣除 公司回购专用账户股份数量）的7.8443％。 （1）现场会议时间：2026 年 1 月 16 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的 具体时间为 2026 年 1 月 16 日 9:15-9: ...

Core Viewpoint - In recent trading, Yingke Medical's stock price has shown fluctuations, with a current price of 41.56 yuan per share and a market capitalization of 27.229 billion yuan, reflecting a year-to-date increase of 6.84% [1]. Financial Performance - For the period from January to September 2025, Yingke Medical reported a revenue of 7.425 billion yuan, representing a year-on-year growth of 4.60%. The net profit attributable to shareholders was 924 million yuan, marking a significant increase of 34.47% compared to the previous year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Yingke Medical decreased by 21.11% to 47,300, while the average number of circulating shares per person increased by 25.65% to 9,832 shares [2]. Dividend Distribution - Yingke Medical has distributed a total of 1.903 billion yuan in dividends since its A-share listing, with 245 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders of Yingke Medical include notable entities such as Huabao Zhongzheng Medical ETF and E Fund Growth Enterprise ETF, with some shareholders reducing their holdings while others, like Hong Kong Central Clearing Limited, increased theirs [4].

Group 1 - The Biotech Index (970038) closed at 2322.86 points, up 0.43%, with a total transaction volume of 50.71 billion yuan and a turnover rate of 3.77% [1] - Among the index constituents, 23 stocks rose, with Yingke Medical leading at an 8.37% increase, while 27 stocks fell, with Dabo Medical leading the decline at 3.28% [1] - The top ten constituents of the Biotech Index include major companies such as Mindray Medical, which has a weight of 14.57% and a market capitalization of 251.90 billion yuan, and Yuyue Medical, which has a weight of 3.48% and a market capitalization of 45.51 billion yuan [1] Group 2 - The net outflow of main funds from the Biotech Index constituents totaled 643 million yuan, while retail investors saw a net inflow of 771 million yuan [1] - Detailed fund flow data indicates that Yuyue Medical had a net inflow of 35.6 million yuan from main funds, while it experienced a net outflow of 66.06 million yuan from retail investors [2] - Mindray Medical saw a net inflow of 13.7 million yuan from main funds, with retail investors experiencing a net outflow of 36.97 million yuan [2]

Group 1 - The medical device sector increased by 0.66% on January 14, with Sanyou Medical leading the gains [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] - Notable gainers in the medical device sector included Sanyou Medical, which rose by 16.63% to a closing price of 22.30, and Tianzhihang, which increased by 13.25% to 24.95 [1] Group 2 - The medical device sector experienced a net outflow of 428 million yuan from institutional investors and 495 million yuan from retail investors, while retail investors saw a net inflow of 923 million yuan [2] - The individual stock fund flow data indicated that Yuyue Medical had a net inflow of 356 million yuan from institutional investors, while it faced a net outflow of 66.06 million yuan from retail investors [3] - Other companies like Yingke Medical and Weili Medical also showed significant net inflows from institutional investors, with 105 million yuan and 90.06 million yuan respectively [3]

Group 1 - The core viewpoint of the report is that Guosen Securities has given a "better than market" rating to Yingke Medical (300677.SZ) due to its leading position in the global disposable glove market and its diversified business layout with significant global advantages [1] - Yingke Medical's competitive edge is attributed to its multi-dimensional cost barriers and global operational capabilities, which are essential in the disposable glove industry [1] - The report highlights that the supply-demand dynamics in the disposable glove industry are continuously improving as market disruptions are clearing [1]